WIN2012 Symposium on Personalized Cancer Medicine Receives Endorsements from ASCO, ESMO, UICC and INCa

PARIS - Wednesday, March 7th 2012 [ME NewsWire]

(BUSINESS WIRE)-- The upcoming annual symposium of the Worldwide Innovative Networking Consortium on personalized cancer medicine (WIN 2012), to be held in Paris, June 28-29, 2012, has received endorsements from the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the Union for International Cancer Control (UICC) and also the French national cancer institute (INCa).
"The value of the symposium scientific program for the oncology community is reinforced by these recently granted endorsements" said Dr. John Mendelsohn, Chairman of the WIN Consortium.
"These endorsements acknowledge this unique forum for open discussion in which the expertise and input from all stakeholders in targeted cancer drug development are crucial" said Alexander Eggermont, General Director of Cancer Institute Gustave Roussy.
High-ranking speakers from academia, industry and regulatory agencies worldwide will address ways to improve the efficacy of cancer therapeutics at the level of the individual patient in plenary sessions on contemporary themes in personalized medicine. Speakers include: James Doroshow, National Cancer Institute;Ronald DePinho, University of Texas MD Anderson Cancer Center; William Dalton, Lee Moffitt Cancer Center; Edison Liu, Human Genome Organisation HUGO and Jackson Laboratory; Christopher A. Viehbacher, Sanofi;Leroy Hood, Institute for Systems Biology; Stephen Friend, Sage Bionetworks;John Quackenbush, Dana-Farber Cancer Institute; Waun Ki Hong, University of Texas MD Anderson Cancer Center;Nick Botwood, AstraZeneca; Steven Averbuch, Bristol-Myers Squibb;Richard Gaynor, Eli Lilly and Company; Paolo Paoletti, GlaxoSmithKline Oncology; Josep Tabernero, Val d’Hebron.
The scientific program of WIN2012 is offered as accredited learning for medical oncologists, valid for 17 ESMO MORA cat. 1 points. To further enhance the scientific value of WIN 2012, all abstracts of presentations (oral and poster) will be published in a major international oncology journal. Abstract submission remains open until April 1.
Delegates considering participating in WIN 2012 are encouraged to register as soon as possible to take advantage of the significantly reduced early registration fees and the special hotel offer the WIN 2012 organizers have managed to secure.
Extensive symposium information, including the complete program with all speakers’ names, is available on the website of WIN Consortium: www.winconsortium.org.

---

Contacts

Vladimir Lazar, +33 142 11 40 20
Chief Operating Officer
vladimir.lazar@igr.fr


Catherine Bresson
Director Operational Team
catherine.bresson@winconsortium.org


WIN 2012 Symposium Secretariat
tel. +31 88 089 8101
win@congressbydesign.com